Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

TECHNICOLOR CS Stock Is 21% Down In The Last 10 Sessions

Loading stream...

(vianews) - shares of technicolor cs (cac 40: tchcs.pa) fell by a staggering 21.62% in 10 sessions from €0.24 to €0.19 at 19:07 est on wednesday, after two sequential sessions in a row of losses. cac 40 is sliding 0.13% to €7,299.26, after three sequential sessions in a row of losses.

about technicolor cs

technicolor creative studios provides visual effects and creative production services to the global entertainment, brand experience, and advertising sectors. the company was founded in 2021 and is based in paris, france. technicolor creative studios is a former subsidiary of technicolor sa.

volatility

technicolor cs's last week, last month's, and last quarter's current intraday variation average was a negative 1.33%, a negative 1.72%, and a positive 3.85%.

technicolor cs's highest amplitude of average volatility was 1.96% (last week), 3.23% (last month), and 3.85% (last quarter).

more news about technicolor cs (tchcs.pa).

Categories

stockMarket

Tags

Stock PricePrice DownMarket Session NowTCHCS.PAStock Price DownStock Market NowMarket SessionStock MarketStockTECHNICOLOR CS
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com